Vaxcyte, Inc. (FRA:5VA)
Germany · Delayed Price · Currency is EUR | Market Cap | 7.54B +122.9% |
| Revenue (ttm) | n/a |
| Net Income | -931.55M |
| EPS | -6.69 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 50.00 |
| Previous Close | 49.00 |
| Day's Range | 50.00 - 50.00 |
| 52-Week Range | 24.80 - 55.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About Vaxcyte
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused b... [Read more]
News
Vaxcyte Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
OPUS-1 phase III data for VAX-31, targeting broader pneumococcal coverage and improved immune response, will be released by end of October. Commercial and manufacturing strategies are in place, with a focus on resolving current market trade-offs and scaling post-data.
Vaxcyte Transcript: Wells Fargo 21st Annual Healthcare Conference
The session highlighted advances in vaccine technology enabling broader and more effective pneumococcal vaccines, with pivotal phase III data for VAX-31 expected by October. Regulatory momentum and market dynamics favor broader coverage, and a novel group A strep vaccine is advancing in early trials.
Vaxcyte names Luis Jodar chief medical officer, David McAvoy chief legal officer
Vaxcyte (PCVX) announced the appointments of Luis Jodar as chief medical officer and David McAvoy as chief legal officer. Jodar spent 17 years at Pfizer (PFE), most recently as senior…
Vaxcyte narrows previously communicated VAX-31 guidance
The company also announced that topline safety, tolerability and immunogenicity data from the VAX-31 adult Phase 3 OPUS-1 trial are now expected by the end of October, narrowing its previously…
Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data
Luis Jodar, Ph.D., Former Pfizer Chief Medical Officer for Vaccines and Infectious Diseases with Extensive Leadership Experience Across Clinical Development and Medical Affairs for Pneumococcal Conjug...
Vaxcyte Slides: Corporate presentation
Vaxcyte has posted slides in relation to its latest quarterly earnings report, which was published on September 3, 2026.
Vaxcyte to Participate in Upcoming Investor Conferences
SAN CARLOS, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in fireside ch...
Vaxcyte reports Q2 EPS ($1.97), consensus ($2.10)
“With the VAX-31 OPUS-1, OPUS-2 and OPUS-3 Phase 3 trials and the VAX-31 Phase 2 infant study fully enrolled, we expect a series of meaningful clinical study readouts across our…
Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update
Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Adult Phase 3 OPUS-1 Trial Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Phase 3 Results Expected in First Half of 2027 Topline...
Vaxcyte Slides: Corporate presentation
Vaxcyte has posted slides in relation to its latest quarterly earnings report, which was published on August 5, 2026.
Vaxcyte Quarterly report: Q2 2026
Vaxcyte has published its Q2 2026 quarterly earnings report on August 5, 2026.
Vaxcyte Earnings release: Q2 2026
Vaxcyte released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Vaxcyte Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and an advisory vote on executive compensation, with all proposals passing by a wide margin. No questions were raised by shareholders during the meeting or Q&A.
Vaxcyte Transcript: Jefferies Global Healthcare Conference 2026
The discussion highlighted a robust pipeline leveraging a proprietary platform, with pivotal phase III adult pneumococcal vaccine data expected soon and a strong competitive position as rivals exit the field. Regulatory strategy focuses on totality of data, and a new Group A Strep program addresses a major unmet need.
Vaxcyte doses first participant in VAX-A1 study
Vaxcyte (PCVX) announced that the first participant was dosed in the Phase 1, first-in-human study evaluating VAX-A1, the company’s investigational prophylactic vaccine candidate for the prevention of...
Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults
First-in-Human Study Evaluating VAX-A1, a Potential Best-in-Class Vaccine Candidate Designed to Provide Broad Protection Against Disease Caused by Group A Streptococcus
Vaxcyte Slides: Corporate presentation
Vaxcyte has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
Vaxcyte Transcript: Bank of America Global Healthcare Conference 2026
VAX-31's phase III program is fully enrolled, with pivotal data expected in Q4 2024. The vaccine targets 31 serotypes, aiming for broader coverage and robust immune responses compared to current standards. Regulatory and commercial preparations are advancing, with market launch targeted for late 2025.
Vaxcyte reports Q1 EPS ($2.30), consensus ($1.77)
The company said, “With the recent completion of OPUS-3 enrollment, our OPUS-1, OPUS-2 and OPUS-3 adult Phase 3 trials are now fully enrolled, and we remain on track to deliver…
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
Enrollment Now Completed for OPUS-1, OPUS-2 and OPUS-3 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
Vaxcyte Quarterly report: Q1 2026
Vaxcyte has published its Q1 2026 quarterly earnings report on May 6, 2026.
Vaxcyte Earnings release: Q1 2026
Vaxcyte released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Vaxcyte Slides: Corporate presentation
Vaxcyte has posted slides in relation to its latest quarterly earnings report, which was published on May 5, 2026.
Vaxcyte Proxy statement: Proxy filing
Vaxcyte filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Vaxcyte Proxy statement: Proxy filing
Vaxcyte filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.